Cite
APA Citation
Cohen, S. B., Czeloth, N., Lee, E., Klimiuk, P. A., Peter, N., & Jayadeva, G. (2019). long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). Expert opinion on biological therapy, 19, 1097–1105. http://access.bl.uk/ark:/81055/vdc_100101545511.0x000035